Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1
- SNCVL Pushpavalli†1,
- M Janaki Ramaiah†1,
- Ch Srinivas1,
- Debasmita Mukhopadhya1,
- JL Aditya2,
- Ravindra M Kumbhare3,
- Utpal Bhadra2Email author and
- Manika Pal Bhadra1Email author
© Pushpavalli et al; licensee BioMed Central Ltd. 2011
Received: 21 June 2011
Accepted: 28 October 2011
Published: 28 October 2011
Hepatocellular carcinoma (HCC) accounts for majority of liver cancers and is the leading cause of cancer related death in Asia. Like any other cancer, HCC develops when there is a mutation to the cellular machinery that causes the cell to replicate at a higher rate and results in the loss of apoptosis. Therefore, a delicate balance between the expression of various genes involved in proliferation and apoptosis decide the ultimate fate of the cell to undergo rapid proliferation (cancer) or cell death.
The benzothiazole based compounds exhibited effective cytotoxicity at 4 μM concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation.
The cell cycle arrest and apoptotic inducing nature of these compounds was revealed by FACS, BrdU cell proliferation and tunel assays. Compounds affected both tumour suppressor proteins as well as proteins that are involved in active cell proliferation. Micro RNAs whose target is Cyclin D1 such as miR-195a and miR-101-1 that is required for growth of hepatoma cells was drastically affected. These compounds caused apoptosis by activating caspase-3 and PARP.
Hepato cellular carcinoma (HCC) is one among the most prevalent and lethal cancers in humans  and is the fifth leading cause of cancer across the world. Majority of the patients with HCC do not survive because of the frequent recurrence of tumour and metastasis. With the recent developments in the field of molecular oncology, researchers have focussed their efforts towards the control of HCC [2, 3]. The key signalling molecules that are frequently activated and involved in human hepatoma are Ras, ERK (extracellular signal regulated kinase) and AKT . Phosphotidyl inositol-3-kinase (PI3K/AKT) constitute an upstream important pathway that regulates the processes of cell growth, metabolism, proliferation and apoptosis . Mitogen activated protein kinases (MAPKs) such as ERK1/2, JNK (c-Jun NH2-terminal kinase), and p38 MAPK belongs to serine/threonine kinase protein family that mediates the intracellular signals in response to various extracellular stimuli. Among these, ERK 1/2 mainly functions in controlling cell division and is considered to provide survival signals that can lead to rapid rate of cell proliferation . Hence inhibitors of ERK are being explored for their anti-cancer properties.
Earlier studies have indicated that HCC may be the cumulative result of inactivation of tumour suppressor gene and activation of multiple oncogenes . PTEN and p53 mainly functions as tumour suppressors and regulate the process of apoptosis . Apoptosis is a programmed cell death which is characterized by events like cytoplasmic shrinkage, chromatin condensation, plasma membrane blebbing, exposure of phosphotidyl serine (PS) of the cell membrane from interior to exterior . Resistance to apoptosis was reported to be a significant factor for hepato-carcinogenesis . Thus compounds having apoptotic inducing nature will certainly play a crucial role in preventing the rapid cell proliferation and ultimately hepatocarcinoma.MicroRNAs (miRNAs) are a class of phylogenetically conserved short RNAs that suppress protein expression through base-pairing with the 3'-untranslated region (3'-UTR) of target mRNA. MicroRNAs are known to play important roles in cell growth, differentiation, proliferation and apoptosis. MiRNAs associated with tumourigenesis act as either tumour suppressors or oncogenes  and are used as potential diagnostic or therapeutic targets in cancer treatment . Although aberrant microRNA (miRNA) expression has been observed in different types of cancer, their pathophysiological role and their relevance to tumourigenesis are still largely unknown. Drastic downregulation of miR-195a, miR-101-1 has been observed in hepatoma (metastasis) [13, 14].
Earlier studies have demonstrated the anti-angiogenesis nature of YM compound in HUVEC cells but a detailed study regarding the pathway has so far not been carried out. In the present study we have focussed mainly on the pathway targeted by benzothiazole conjugates which results in effective cytotoxicity in hepatoma cells by modulating the expression of both oncogenic and tumour suppressor proteins.
Benzothiazole based compounds induce Cytotoxicity
Effect of Benzothiazole based compounds on Cell Cycle
In order to understand whether benzothiazole based compounds (A3 and A4) have any regulatory role on cell cycle, FACS analysis was conducted. HepG2 cells were treated with compounds YM, A3 and A4 for 24 h. Treatment of cells with compounds A3 and A4 caused G1 cell cycle arrest, whereas YM the standard drug has caused G2/M cell cycle arrest. The percentage of cells in the G1 phase was 87 and 90 in case of A3 and A4 compound treated cells respectively. YM has shown 25% cells in G2/M phase and control untreated cells have shown 69% and 21% in G1 and G2/M phases respectively (Figure 3B). The G1 cell cycle arrest caused by A3 and A4 compounds were further confirmed by BrdU cell proliferation assay which reveals whether the cells are arrested in G1 or progressing to S phase of cell cycle. Here the control and YM treated cells have not shown any change in the O.D values whereas A3 and A4 treated cells have shown reduction, confirming the G1 phase arrest caused by these compounds (Figure 3C).
Effect of Benzothiazole based compounds on cell cycle regulatory proteins
Benzothiazole based compounds activate tumour suppressor proteins p53 and PTEN
P53 and PTEN are tumour suppressor proteins that control the apoptotic event. p53 function is crucial in multicellular organisms, where it regulates cell cycle and thus functions as a tumour suppressor that is involved in preventing cancer. PTEN is one of the most commonly lost tumour suppressors in human cancer. In order to understand the effect of these compounds on tumour suppressor proteins HepG2 cells were treated with compounds YM, A3 and A4 for 24 h and cell lysates were subjected to western analysis. An increase in the expression of both these proteins was seen upon treatment of the compounds (YM, A3 and A4) in comparison to control untreated cells indicating an effect in the upregulation of both the genes.
Effect of Benzothiazole based compounds on Ras and MAP Kinase family proteins
Cytotoxicity induced by benzothiazole based compounds
Effect of benzothaizole based compounds on miR-195a and miR-101-1
Liver cancer is fatal and occurs commonly in Asian countries . Hepato cellular carcinoma is characterised by rapid growth rate, strong malignancy, easy invasion, metastasis and poor prognosis. The development of chemotherapeutic agents that cause apoptosis and reduce mortality have been increasingly appreciated as ideal compounds for management of this cancer . We have synthesised analogs of benzothiazoles (A3, A4) and carried out detailed biological study in order to understand the key signalling molecules that are affected and are responsible for the cytotoxic nature. In the present study benzothiazole conjuagates (A3 & A4) have shown profound cytotoxicity (50% of cell death) at 4μM concentration as observed by MTT based cell viability assay. The apoptosis inducing nature of the compounds was clearly demonstrated by Hoechst nuclear staining as well as tunnel assay which revealed blebbing and DNA fragmentation that occurred during cell death. The FACS analysis of A3 and A4 compound treated cells indicated G1 cell cycle arrest nature which was further confirmed by BrdU cell proliferation assay. The G1 to S phase transition of cell cycle is mainly controlled by proteins such as Cyclin D1 and Skp2. Perturbations in Cyclin D1 and its impact on hepatocarcinoma has been widely observed in 30 different hepatoma types . Where as Skp2 plays a prominent role in the process of degradation of the tumour suppressor proteins such as Foxo that controls the G1 to S phase transition. In our study we found drastic down regulation of Cyclin D1and Skp2 proteins after compound treatment there by revealing G1 cell cycle arrest nature of the benzothiazole based compounds (Figure 4).
It has been reported that hepato-cellular carcinoma is the final event of inactivation of tumour suppressor genes such as PTEN and p53 that controls cell proliferation and death [7, 8]. Upon compound treatment upregulation of PTEN and p53 protein levels was observed by western analysis. This data has been further supported by the fact that increased p53 level resulted in increased binding of p53 to PTEN promoter and controls both the transcriptional and translational regulation of PTEN gene which aids in increased rate of apoptosis .
Increased PTEN, apart from acting as tumour suppressor negatively regulates AKT activity (i.e AKT phosphorylation) and cause apoptosis . Moreover AKT physically associates with MDM2 and phosphorylates at serine residue which helps in nuclear translocation thereby causing degradation of p53 . In the present study we observed increased PTEN which causes decreased AKT activity (phosphorylation) and finally leading to p53 activation. Another important protein family that plays a major role in the formation, migration, invasion and maintainence of hepatocarcinoma is MAPK protein family. Mitogen activated protein kinase (MAPK) family members such as MAPK and ERK1/2 are important proteins that functions as intracellular signal transducers which enter into the nucleus upon phosphorylation  and induce genes involved in the process of proliferation and differentiation  & . Interestingly treatment of HepG2 cells with the compounds (A3 & A4) resulted in the decrease of phosphorylated forms of P38 MAPK and ERK1/2 proteins thus controlling active cell proliferation.
Recent studies have indicated that micro RNAs are directly involved in many different kinds of cancers such as lung, breast, brain, liver, colon and leukemia. More than 50% of miRNA genes are located in cancer associated genomic regions or in the fragile sites suggesting that miRNAs may play a vital role in the pathogenesis of human cancers . Interestingly degradation of microRNAs has been frequently observed in tumour tissues [30, 31]. In 80-90% of hepato cellular carcinoma (HCC) cases microRNAs such as miR-195 and miR-101-1 were found to be down regulated. Ectopic expression studies of miR-195 caused G1/S phase block by targeting cyclin D1  whereas miR-101-1 dramatically suppresses the ability of hepatoma cells to form colonies and develop tumours . Upon compound treatment (A3 and A4) the expression of miRNAs (miR-195, miR-101-1) was significantly increased and thus has potential implication in the treatment of hepatoma. Previous studies [32–34] have shown the role of caspase-3 and cleavage of PARP in the process of apoptosis. The benzothiazole compounds in the present study have also shown the involvement of mitochondria through the activation of caspase-3 and PARP proteins.
Benzothiazole based compounds (A3, A4) exhibited high cytotoxic activity as observed from the MTT studies. Cell cycle analysis has shown the G1 cell cycle arrest nature of the compounds and was further confirmed by BrdU cell proliferation assay. Our compounds A3 and A4 regulate cell cycle by affecting cyclin D1 and Skp2 that play a vital in controlling G1-S phase of cell cycle. The balance between genes involved in cell proliferation and tumour suppression regulate the events of tumourigenesis or apoptosis. Compound treated cells have exhibited increased levels of tumour suppressor proteins PTEN and p53. The phosphorylated (active) forms of ERK1/2 and p38 MAPK protein levels were decreased in compound treated cells which led to control of cell proliferation. The levels of microRNAs such as miR-195a, miR-101-1 were elevated in A3 and A4 compound treated cells compared to control untreated cells. These compounds caused cell death involving mitochondria as the major organelle with the activation of active caspase-3 and PARP proteins. Thus these benzothiazole based conjugates have potential implications in control of hepato-cellular carcinoma.
Human hepato-carcinoma cell line HepG2 purchased from American Type culture collection was maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen), supplemented with 2 mM glutamax (Invitrogen), 10% fetal calf serum and 100 U/ml Pencillin and 100 mg/ml streptomycin sulfate (Sigma). The cell line was maintained at 37°C in a humidified atmosphere containing 5% CO2 in the incubator.
Cell viability was assessed by MTT assay, a mitochondrial function assay. It is based on the ability of viable cells to reduce the MTT to insoluble formazan crystals by mitochondrial dehydrogenase. HepG2 cells were seeded in a 96-well plate at a density of 10,000 cells/well. After overnight incubation, cells were treated with compounds YM, A3 and A4 at 4 and 8 mM concentration and incubated for 24 h. Medium was then discarded and replaced with 10 μL MTT dye. Plates were incubated at 37°C for 2 h. The resulting formazan crystals were solubilized in 100 μL extraction buffer. The optical density (O.D) was read at 570 nm with micro plate reader (Multi-mode Varioskan instrument-Themo Scientific).
Cell Cycle Analysis
5 × 105 HepG2 cells were seeded in 60 mm dish and were allowed to grow for 24 h. Compounds A3, A4 and YM were added at a final concentration of 4μM to the culture media, and the cells were incubated for an additional 24 h. Cells were harvested with Trypsin-EDTA, fixed with ice-cold 70% ethanol at 4°C for 30 min, washed with PBS and incubated with 1 mg/ml RNase A solution (Sigma) at 37°C for 30 min. Cells were collected by centrifugation at 2000 rpm for 5 min and further stained with 250 mL of DNA staining solution [10 mg of Propidium Iodide (PI), 0.1 mg of trisodium citrate, and 0.03 mL of Triton X-100 were dissolved in 100 mL of sterile MilliQ water at room temperature for 30 min in the dark]. The DNA contents of 20,000 events were measured by flow cytometer (DAKO CYTOMATION, Beckman Coulter, Brea, CA). Histograms were analyzed using Summit Software.
Tunel assay was conducted by using the Apoalert DNA fragmentation Assay kit (Clone tech) according to manufacturer instructions. This kit detects the apoptosis-induced nuclear DNA fragmentation that is based on fluorescence. The assay is based on the principle of terminal deoxy nucleotidyl transferase (TdT)-mediated dUTP nick-end-labelling (i.e TUNEL). TdT catalyzes incorporation of fluorescein-dUTP at the free 3'-hydroxyl ends of fragmented DNA. Flourescein-labeled DNA can be detected via confocal microscopy.
BrdU Cell Proliferation Assay
This assay was carried out by using the 5-Bromo 2-deoxyuridine (BrdU) cell proliferation assay kit (Millipore) to assess the effect of YM, A3 and A4 compounds on the proliferation of HepG2 cells. 1 × 104cells were seeded and allowed to grow for 24 h. BrdU was added and allowed to incorporate for 5 h followed by the addition of test compound (YM, A3 & A4) at concentration of 4 μM for 24 h. Fixation was done for 30 min at room temperature. The cells were then washed, anti-BrdU antibody was added which binds to BrdU that was incorporated in the cell. After 1 h incubation, 100 μl anti-BrdU goat anti-mouse horse raddish peroxidise (HRP)- conjugated secondary antibody (1:2000) was added and incubated for 30min. Washing procedures were followed according to the manufacturer's instructions. TMB substrate (100 μl) was added, incubated for another 30min at room temperature and O.D values were taken at a wave length of 450nm. Lower O.D values reflect lower BrdU concentrations in the sample and thus an indirect depiction of a low cell proliferation rate.
Human hepato-carcinoma HepG2 cells were seeded on cover slips and treated with benzo-thiazole based compounds at concentration of 4 μM for 24h. After treatment, cover slips were fixed with a paraformaldehyde solution (4% in 1× PBS) for 20 min at room temperature. Cell permeabilization was achieved by administration of a Triton X-100 solution (0.2% in 1× PBS) for 5min. Further the cover slips were kept overnight in 100% methanol at 4°C. Subsequently, cover slips were blocked with a 1% BSA solution for 60min and then incubated with anti PTEN (1:100) antibody at room temperature for 2h. The slides were washed three times each of 5min with PBST. Then cover slips were incubated with a FITC-conjugated anti-rabbit secondary antibody (Jackson Immuno Research Laboratories Inc., Pennsylvania, USA) for one hour and cover slips were washed three times with PBST solution and mounted with DAPI/PI solution. Finally, cells were observed under confocal microscope (Olympus FV1000). Images taken were processed with the support of the flow view version 1.7 c software program.
Protein extraction and Western blot analysis
Total cell lysates from cultured HepG2 cells were obtained by lysing the cells in ice-cold RIPA buffer (1XPBS, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) and containing 100 mg/mL PMSF, 5 mg/mL Aprotinin, 5 mg/mL leupeptin, 5 mg/mL pepstatin and 100 mg/mL NaF. After centrifugation at 12,000 rpm for 10 min, the protein in supernatant was quantified by Bradford method (BIO-RAD) using Multimode Varioskan instrument (Thermo-Fischer Scientifics). Fifty micrograms of protein per lane was applied in 12% SDS-polyacrylamide gel. After electrophoresis, the protein was transferred to polyvinylidine difluoride (PVDF) membrane (GE Biosciences). The membrane was blocked at room temperature for 2 h in TBS + 0.1% Tween20 (TBST) containing 5% blocking powder (Santacruz). The membrane was washed with TBST for 5 min, primary antibody was added and incubated at 4°C overnight (O/N). ERK 1/2, ERK Phos (Thr 202/Tyr 204), Phos p38 (Thr 180/Tyr 182), P38MAPK, active caspase-3 and Cleaved PARP antibodies were purchased from Cell Signalling, USA. P53 and Cyclin D1antibodies were purchased from Santa Cruz, PTEN and Skp2 antibodies were purchased from Abbiotec Company. Akt Ser 473 antibody was purchased from (Millipore). The membrane was incubated with corresponding horseradish peroxidase-labeled secondary antibody (1:2000) (Santa Cruz) at room temperature for 1h. Membranes were washed with TBST three times for 15 min and the blots were visualized with chemiluminescence reagent (Thermo Fischer Scientifics Ltd.). The X-ray films were developed with developer and fixed with fixer solution.
HepG2 cells were seeded on cover slips, treated with compounds for 24h, washed with PBS and fixed with 4% Paraformaldehyde for 15min at room temperature. Fixed cells were incubated in PBS (pH 7.4) containing DNAse-free RNase (Sigma) for 30 min at 37°C and stained with Hoechst. Nuclear morphology of the cells was observed under confocal microscope.
Semi-quantitative Reverse Transcription PCR (RT-PCR)
List of primer sequences used for RT-PCR
K Ras -FP
K Ras -RP
MicroRNA Expression profiling
Total RNA was isolated from control and compound (A3 and A4) treated cells. Equal amount of DNase-treated RNA was Poly A tailed using Poly A Polymerase and oligo dT adapter was used to synthesise the cDNA. RT-PCR reaction was set up using universal reverse primer and miRNA specific forward primer. The temperature conditions are 50°C for 2min, 95°C 10min, followed by 40 cycles of (95°C 15sec, 60°C 1min).
Statistical Analysis was performed using the graph pad software to evaluate the significant difference between the control and treated samples. All variables were tested in three independent experiments. The results were reported as mean ± SD. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001.
Extracellular signal-regulated kinases
Mitogen-activated protein kinase
Phosphatase and tensin homolog
This research is fully funded by Supra-institutional project (SIP-0011), CSIR, INDIA and Wellcome Trust UK (GAP 0158).
- Farazi PA, Glickman J, Horner J, Depinho RA: Cooperative interactions of p53 mutation, telomere dysfunction and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006, 66 (9): 4766-73. 10.1158/0008-5472.CAN-05-4608.View ArticlePubMedGoogle Scholar
- Lo A, Lin CT, Wu HC: Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008, 7 (3): 579-89. 10.1158/1535-7163.MCT-07-2359.View ArticlePubMedGoogle Scholar
- Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X, Lu CX: PTEN inhibits the migration and invasion of HepG2 cells by co-ordinately decreasing MMP expression via PI3K/AKT pathway. Oncol Rep. 2010, 23 (6): 1593-1600.PubMedGoogle Scholar
- Charette N, Saeger CD, Lannoy V, Horsmans Y, Leclerq I, Starkel P: Salirasib inhibits the growth of hepato carcinoma cell lines invitro and tumour growth invivo through ras and mTOR inhibition. Mol Cancer. 2010, 9: 256-10.1186/1476-4598-9-256.PubMed CentralView ArticlePubMedGoogle Scholar
- Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des. 2010, 16 (1): 34-44. 10.2174/138161210789941865.View ArticlePubMedGoogle Scholar
- Johnson GL, Lapadat R: Mitogen- activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 2002, 298 (5600): 1911-12. 10.1126/science.1072682.View ArticlePubMedGoogle Scholar
- Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene. 2002, 21: 4932-4943. 10.1038/sj.onc.1205652.View ArticlePubMedGoogle Scholar
- Yamada KM, Araki M: Tumour suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J cell Sci. 2001, 114: 2375-2382.PubMedGoogle Scholar
- Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem. 2000, 69: 217-245. 10.1146/annurev.biochem.69.1.217.View ArticlePubMedGoogle Scholar
- Ikeguchi M, Hirooka Y, Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepato cellular carcinoma. Cancer. 2002, 95 (9): 1938-1945. 10.1002/cncr.10898.View ArticlePubMedGoogle Scholar
- Lynam-Lennon N, Maher SG, Reynolds JV: The roles of micro RNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009, 84 (1): 55-71. 10.1111/j.1469-185X.2008.00061.x.View ArticlePubMedGoogle Scholar
- Hummel R, Hussey DJ, Haier J: Micro RNAs: predictors and modifiersof chemo- and radiotherapy in different tumour types. Eur J cancer. 2010, 46 (2): 298-311. 10.1016/j.ejca.2009.10.027.View ArticlePubMedGoogle Scholar
- Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhung SM: Micro RNA-195 suppresses tumourigenicity and regulates G1/S transition of human hepato cellular carcinoma cells. Hepatology. 2009, 50 (1): 113-21. 10.1002/hep.22919.View ArticlePubMedGoogle Scholar
- Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: Micro RNA- 101, down regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumourigenicity. Cancer Res. 2009, 69 (3): 1135-1142. 10.1158/0008-5472.CAN-08-2886.View ArticlePubMedGoogle Scholar
- Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Matsuhisa A, Kudoh M, Shibasaki M: YM-201627: An orally active antitumour agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett. 2006, 238: 119-127. 10.1016/j.canlet.2005.06.037.View ArticlePubMedGoogle Scholar
- Cardones AR, Banez LL: VEGF inhibitors in cancer therapy. Curr Pharm Design. 2006, 12 (3): 387-394. 10.2174/138161206775201910.View ArticleGoogle Scholar
- Davies MA, Lu Y, Sano T, Fang X, Tang P, Lapushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998, 58: 5285-5290.PubMedGoogle Scholar
- Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007, 117 (9): 2713-2722. 10.1172/JCI31457.PubMed CentralView ArticlePubMedGoogle Scholar
- Fan J, Bertino JR: K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997, 14: 2595-2607. 10.1038/sj.onc.1201105.View ArticlePubMedGoogle Scholar
- Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH-3T3 cells. Cell. 1994, 77 (6): 841-852. 10.1016/0092-8674(94)90133-3.View ArticlePubMedGoogle Scholar
- Sale EM, Atkinson PG, Sale GJ: Requirement of MAPKinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J. 1995, 14 (4): 674-684.PubMed CentralPubMedGoogle Scholar
- Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP Kinase pathway. Oncogene. 2000, 19 (56): 6594-9. 10.1038/sj.onc.1204083.View ArticlePubMedGoogle Scholar
- Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000: Based on registered data from 131 hospitals. Cancer Res Treat. 2002, 34 (2): 77-83.Google Scholar
- Debatin KM: Activation of apoptosis pathways by anti-cancer drugs. Adv Exp Med Biol. 1999, 457: 237-244. 10.1007/978-1-4615-4811-9_25.View ArticlePubMedGoogle Scholar
- Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and over expression of Cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993, 196 (2): 1010-1016. 10.1006/bbrc.1993.2350.View ArticlePubMedGoogle Scholar
- Stambolic V, Mac Pherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW: Regulation of PTEN transcription by p53. Mol Cell. 2001, 8 (2): 317-325. 10.1016/S1097-2765(01)00323-9.View ArticlePubMedGoogle Scholar
- Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 1997, 94: 2479-12484.View ArticleGoogle Scholar
- Mayo LD, Donner DB: A phosphatidyl inositol 3- kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001, 98 (20): 11598-11603. 10.1073/pnas.181181198.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang B, Pan X, Cobb GP, Anderson TA: Micro RNAs as oncogenes and tumour suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.View ArticlePubMedGoogle Scholar
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: Micro RNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-8. 10.1038/nature03702.View ArticlePubMedGoogle Scholar
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A micro RNA expression signature of human solid tumours defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103 (7): 2257-61. 10.1073/pnas.0510565103.PubMed CentralView ArticlePubMedGoogle Scholar
- Cohen GM: Caspases: the executioners of apoptosis. Biochem J. 1997, 326: 1-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA: Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science. 2006, 311 (5762): 847-851. 10.1126/science.1115035.PubMed CentralView ArticlePubMedGoogle Scholar
- Sethi G, Sung B, Aggarwal BB: Flavopiridol suppresses tumour necrosis factor induced activation of activator protein-1, C-Jun N-terminal kinase, p38 mitogen activated protein kinase (MAPK), p44/p42 MAPK and Akt, inhibits expression of antiapoptotic gene products and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Molecular Pharmacol. 2008, 73: 1549-1557. 10.1124/mol.107.041350.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.